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Introduction: Postoperative nausea and vomiting (PONV) is one of the most common
complaints from patients and clinicians after a surgical procedure. According to the current
Society of Ambulatory Anesthesia Consensus Guidelines, the general incidence of vomiting
and nausea is around 30 and 50%, respectively; and up to 80% in high-risk patients. In
previous studies, the reported incidence of PONV at 24 h after craniotomy was 43–70%. The
transdermal scopolamine (TDS) delivery system contains a 1.5-mg drug reservoir, which is
designed to deliver a continuous slow release of scopolamine through intact skin during the
first 72 h of patch application. Therefore, we designed this single arm, non-randomized, pilot
study to assess the efficacy and safety of triple therapy with scopolamine, ondansetron, and
dexamethasone to prevent PONV.
Materials and methods: In the preoperative area, subjects received an active TDS 1.5mg
that was applied to a hairless patch of skin in the mastoid area approximately 2 h prior to the
operation. Immediately after anesthesia induction, all patients received a single 4mg dose
of ondansetron IV and a single 10mg dose of dexamethasone IV. Patients who experienced
nausea and/or vomiting received ondansetron 4mg IV as the initial rescue medication.
Postoperative nausea and vomiting assessments were performed for up to 120 h after
surgery.
Results: A total of 36 subjects were analyzed. The overall incidence of PONV during the first
24 h after neurological surgery was 33% (n=12). The incidence of nausea and emesis during
the first 24 h after surgery was recorded as 33% (n=12) and 16% (n=6), respectively.
Conclusion:Our data showed that this triple therapy regimen may be an efficient alternative
regimen for PONV prophylaxis in patients undergoing neurological surgery with general
anesthesia. Further studies using regimens affecting different receptor pathways should be
performed to better prove the efficacy and safety in the prevention or delay of PONV.
Keywords: nausea, vomiting, scopolamine, postoperative care, ondansetron
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Introduction
Postoperative nausea and vomiting (PONV) is one of the most
common concerns from subjects and clinicians after a surgical
procedure (1). The literature defines PONV as the presence of
nausea and vomiting during the first 24 hours after a surgical pro-
cedure. PONV can be classified as either early PONV (0–2 hours
(h)) or delayed PONV (2–24 h) (1). Episodes that occur after the
patient has left the institution are known as post-discharge nausea
and vomiting (PDNV) (1, 2). According to the 2014 consensus
guidelines for the management of PONV from the Society of
Ambulatory Anesthesia (SAMBA), the general incidence of vom-
iting and nausea is around 30 and 50%, respectively; and up to
80% in high-risk patients (three and more risk factors) (1). The
increase in central venous pressure (CVP) that results from the
act of retching can lead to potentially severe complications in
certain surgical populations. For instance, in craniotomy patients,
this increase in CVP could presumably lead to postoperative
intracranial hemorrhage or worsening of intracranial pressure (3).
In previous studies, the reported incidence of PONV at 24 h after
craniotomy was 43–70% (4–7).
Ondansetron is a serotonin (5HT3) receptor antagonist most
used in PONV trials and is considered the “gold standard”
antiemetic due to its efficacy and low cost (1, 6, 9, 10, 14–18).
This drug’s short half-life of around 4 h and its lack of seda-
tive effect make it an excellent option in the neurosurgical field
(1, 4, 10). The corticosteroid dexamethasone is another medi-
cation widely used for PONV prophylaxis; its intravenous (IV)
administration after anesthesia induction is recommended, and
it has similar efficacy for PONV prophylaxis as ondansetron (1,
4). Scopolamine is considered a non-polar, tertiary amino com-
pound, and muscarinic acetylcholine antagonist. As part of its
pharmacodynamic properties, it has an adequate absorption in the
gastrointestinal tract and excellent blood–brain barrier penetra-
tion. Scopolamine has also been reported to be effective in the
prevention of PONV (1, 2, 5, 10, 15, 17, 19–22). The literature
showed that IV or intramuscular scopolamine has a short half-
life in plasma and may lead to dose-dependent side effects such
as excessive drowsiness, agitation, hallucinations, dizziness, dry
mouth, and lethargy. Conversely, transdermal scopolamine (TDS)
releases the drug over a period of 72 h; for this reason, the risks
of plasma concentration-related side effects may be lower due to
the slower rate of transdermal absorption (10). TDS contains a
1.5-mg drug reservoir, which is intended to supply a continuous
slow release of scopolamine through intact skin during the first
72 h of patch application (23). The U.S. Food and Drug Adminis-
tration (FDA) approved the TDS in 1979 as a method of motion
sickness prophylaxis; then, in 2001, it was approved for PONV
prophylaxis (2). PDNV usually remains as unreported events due
to early discharge despite the fact that it is usually documented
by many patients as the most undesirable postoperative event (2,
24). TDS is designed to deliver a constant rate of approximately
1.0mg of scopolamine into the systemic circulation over 72 h and
thus may play an important role to prevent PDNV since it is
designed to deliver scopolamine for 72 h. Multiple studies using
TDS for prophylaxis did not assess PONV 24 h after surgery,
thus data supporting the antiemetic effects for delayed PONV
are lacking (5, 19, 20, 22, 25). Considering the beneficial effects
of TDS, its favorable pharmacokinetic and pharmacodynamic
profile, and the importance of PONV prophylaxis, TDS may turn
into a strong alternative to be one of the first or second line
therapeutic agents for PONV (2). The efficacy of TDS in PONV
prophylaxis is well-established in different studies (1, 5, 9, 15, 19–
22, 26). However, the use of TDS in the neurosurgical field has
not been studied before, probably due to its controversial sedative
side effect and the rare possibility of untoward physical exam
findings from this anticholinergic medication (e.g., dilated pupils)
(2). Therefore, we designed this single arm, non-randomized, pilot
study to assess the efficacy and safety of triple therapy with scopo-
lamine, ondansetron, and dexamethasone to prevent PONV. We
hypothesized that prophylactic triple therapy with scopolamine,
ondansetron, and dexamethasone was an effective and safe treat-
ment for the prevention of PONV in patients with moderate to
high risk of PONV who underwent neurological surgery under
general anesthesia (27).
Materials and Methods
After obtaining institutional review board (Office of Responsible
Research Practices) approval for the research protocol, a total of
44 subjects provided their written informed consent before any
study-specific procedures were done at The Ohio State Univer-
sity Wexner Medical Center. Study inclusion criteria consisted of
neurosurgical subjects scheduled to undergo elective craniotomy
(opening of the cranium and Dura mater) requiring at least 1 h
of general anesthesia with an expected 24 h hospitalization. These
subjects had moderate to severe risk for PONV as assessed by
having two or more risk factors on the simplified Apfel score.
Exclusion criteria consisted of prisoner status, medical history
of alcohol or drug abuse, history of allergic reaction or intoler-
ance to any study medications, pregnant or breastfeeding female
subjects, history of nausea and/or vomiting within 24 h prior
craniotomy, history of treatment with antiemetic medication for
nausea or vomiting within 24 h of their procedure, and history of
chemotherapy treatment within 4weeks prior to surgery. Subjects
who had received anymedication with antiemetic properties were
also excluded from participating in the study.
Prior to surgery, vitals and study safety procedures including
electrocardiogram (ECG) and a urine or serum pregnancy test
were performed. In the preoperative area, subjects received an
active TDS 1.5mg that was applied to a hairless patch of skin
in the mastoid area approximately 2 h prior to the operation.
Immediately after anesthesia induction, all subjects received a
single 4mg dose of ondansetron IV and a single 10mg dose of
dexamethasone IV.
The standardized anesthesia regimen also consisted of pre-
medication of midazolam 1–2mg IV immediately before transfer-
ring the subjects to the operating room. Anesthesia was induced
with propofol 1–2mg/kg IV and fentanyl 0.75–1.5µg/kg IV.
Tracheal intubation was performed after the administration of
rocuronium 0.6–1.2mg/kg 1 IV.
General anesthesia was maintained with volatile anesthetics
(sevoflurane, desflurane, or isoflurane) and its titration con-
centration was guided on clinical judgment. Analgesia during
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anesthesia maintenance was provided with fentanyl boluses of
0.5–2.0µg/kg 1 IV. At the end of the procedure, neostigmine and
glycopyrrolate were used to reverse residual neuromuscular block.
After surgery, subjects were transferred to the surgical intensive
care unit (SICU) or post anesthesia care unit (PACU); subjects
that experienced nausea and/or vomiting received ondansetron
4mg IV as the initial rescue medication for PONV. Choice of
subsequent rescue antiemetic was left to the anesthesiologist’s
discretion.
This pilot study explored the effects of TDS triple therapy on
PONV 24 h postoperative as a primary endpoint. As such, TDS
was removed by the study investigators 24 h after the end of
surgery (defined as discontinuation of the inhaled anesthetic). If
the patch became dislodged from the skin during the first 24 h
after surgery, study investigators reapplied in the same site and
covered with a bandage. Anesthesia and surgical procedure start
and end time, admission and discharge time from the PACU,
SICU, general care floor, total length of stay, and preoperative
Apfel score were recorded. As a secondary outcome, the influ-
ence of this triple therapy administration on delayed PONV was
assessed every 24 h for 5 days via direct interview and/or medical
records review. Intraoperative medication and opioid daily con-
sumption from PACU arrival time through a 5-day follow up were
recorded.
First episode of nausea, vomiting, and rescue medication were
recorded. Nausea was assessed by asking subjects to rate their
nausea on a 0–10 point scale, with 0 being no nausea at all
and 10 being severe nausea. Vomiting was assessed by asking
subjects to rate their vomiting on a 0–3 point scale, with 0 being
no vomiting, 1 being mild vomiting (1–2 episode in 12 h, small
amount of emesis), 2 being moderate vomiting (3–5 episodes in
12 h, breakthrough vomiting), and 3 being severe vomiting (6–7
episodes in 12 h, intractable, incessant, projectile).
For subjects discharged before the end of a 5-day time period,
telephone contact was performed every 24 h to assess nausea
and/or vomiting, rescue medication, opioid consumption, as well
as adverse events and serious adverse events. Following the first
24 h after administration of the prophylactic triple therapy, an
ECG was performed as part of safety assessments.
Results
A total of 44 subjects were enrolled in the study, 6 were considered
screen failures, and 2 were early terminations. Thus, the data from
36 subjects were analyzed. The primary reason for screen failure
was failure to meet all of the inclusion/exclusion criteria (n= 6).
One subject was excluded from the study due to the surgeon’s
decision to remove the TDS before surgery and another due to
change in the surgical procedure from craniotomy to craniectomy
(Figure 1).
Subjects were further analyzed based on whether or not they
experienced any nausea during the first 120 h after the surgery.
The subjects demographic’s, Apfel risk factors for PONV, duration
of anesthesia, duration of PACU stay, duration of SICU stay, dura-
tion of total hospital stay, and postoperative opioid consumption
are listed in Table 1. No adverse events related to the study
medications were observed.
44
Eligible patients  
6
Subjects excluded
38
Received study meds 
2
Subjects early term. 
36
Completed 120 hours
follow-up 
FIGURE 1 | Patient screening flowchart.
TABLE 1 | Patient demographics and surgical variables.
Demographics and surgical variables Scopolamine
group (n= 36)
Age, mean (SD), years 48 (14.6)
Weight, mean (SD), kg 82 (20.4)
Height, mean (SD), cm 169 (9.6)
BMI, mean (SD) 29 (8.2)
ASA I/II/III 1/11/24
Race-White, n (%) 29 (80)
Sex (female) n (%) 22 (61)
Non-smoking status, n (%) 33 (92)
History of PONV and/or motion of sickness n (%) 12 (33)
Postoperative opioids, n (%) 36 (100)
Apfel risk factors, n (%)
2 13 (36.1)
3 15 (42.0)
4 8 (22.0)
Duration of anesthesia, mean (SD), hours 5 (2.8)
Duration of PACU stay, mean (SD), hours 2 (1.0)
Duration of SICU stay, mean (SD), days 2 (2.3)
Duration of total hospital stay, mean (SD), days 3 (3)
Postoperative opioid consumption 0–24, media (IQR) oral
morphine, mg
66 (41–154)
Postoperative opioid consumption 0–48, media (IQR) oral
morphine, mg
123 (45–241)
Postoperative opioid consumption 0–120, media (IQR) oral
morphine, mg
228 (48–416)
The overall incidence of PONV during the first 24 h after
craniotomywas 33% (n= 12). The incidence of nausea and emesis
during the first 24 h after surgery was recorded as 33% (n= 12)
and 16% (n= 6), respectively. The percentage of subjects with
freedom from emesis episodes over 0–24 h postoperatively was
84% (n= 30, 83% CI; 67–93%). Of those that experienced nausea
during the first 24 h after neurological surgery, the median sever-
ity was rated as 8.5 (5.5–10). The median severity of vomiting was
2 (1–2), corresponding to moderate severity. Rescue medication
during the first 24 h was used in 11 subjects (30%). The complete
response and control rate during the first 24 h as 69% (n= 25, 95%
CI: 53–84%) (Table 2).
The mean time to first emetic episode, first rescue, and first
significant nausea was 26.7 (30.2), 19.6 (24.1), 23.6 (27.1)
hours, respectively (Table 3).
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TABLE 2 | Postoperative nausea and vomiting outcome variables (n= 36).
Outcome variables 0–2h 0–24h 24–48h 24–72h 24–96h 24–120h
N % N % N % N % N % N %
Freedom from emesis 35 98 30 84 33 92 32 89 31 86 30 84
Vomiting 1 2 6 16 3 8 4 11 5 14 6 16
Number of vomiting episodes (IQR) 2 (2, 2) 1.5 (1, 3) 1 (1, 4) 1.5 (1, 3) 1 (1, 4) 1 (1, 4)
Vomiting severity (IQR) 2 (2, 2) 2 (1, 2) 3 (2, 3) 2.5 (2, 3) 2 (2, 3) 2.5 (2, 3)
Nausea 4 11 12 33 8 22 12 33 14 38 14 38
Number of nausea episodes (IQR) 2 (1.5, 2.5) 2 (1.5, 3) 2 (1, 4.5) 1 (1, 2) 3.5 (1, 6) 3.5 (1, 8)
Worst nausea score (IQR) 6 (5.5, 8) 8.5 (5.5, 10) 7.5 (5, 10) 7 (5, 9.5) 7 (5, 9) 7 (5, 9)
Complete control 32 89 25 69 32 89 30 83 28 78 27 75
Complete response 32 89 25 69 32 89 30 83 28 78 27 75
Number of rescue therapy 4 11 11 30 2 5 3 8 4 9 4 9
Complete control= no emesis+ no rescue medication+ no nausea>4 (0–10 scale).
Complete response= no emesis+ no rescue medication.
TABLE 3 | Intent to treat population.
Time to treatment failure, mean (SD) Time hours
Scopolamine (n= 36)
Time to first emetic episode 26.7 (30.2)
Time to first rescue 19.6 (24.1)
Time to first significant nausea 23.6 (27.1)
95% Confidence interval for complete response (0–24 h): [0.53, 0.84].
The cumulative overall incidence of PONV during the delayed
period (24–120 h) was 38% (n= 14). The incidence of nausea
and emesis during 24–120 h after surgery was recorded as 38%
(n= 14) and 16% (n= 6), respectively. The percentage of subjects
with freedom from emesis episodes over 24–120 h postoperative
was 84% (n= 30, 83% CI; 67–93%). Of those that experienced
nausea during 24–120 h after neurological surgery, the median
severity was rated as 7 (5, 9). The median severity of vomiting was
1 (1, 4), corresponding tomild severity. Rescuemedication during
24–120 h was used in 4 subjects (9%). The complete response and
complete control rate during 24–120 h was 75% (n= 27, 95% CI:
74–96%).
The median number of vomiting episodes from 0 to 120 h
postoperative ranged between 1 and 1.5 (Table 2).
Discussion
The results of this study demonstrated that the combined use of
TDS, ondansetron, and dexamethasonewas an effective therapy to
prevent nausea and vomiting in subjects undergoing craniotomy
using general anesthesia. This prospective pilot study analyzed
the data of 36 subjects that underwent craniotomy; postoperative
nausea and vomiting assessments were performed for up to 120 h
after surgery.
There is not a single risk factor for PONV that is sensitive
or specific enough to be used alone to assess the risk of PONV.
However, one can combinemultiple independent predictors using
the simplified risk score model from Apfel et al. to help stratify a
patient’s risk for PONV (8). The risk factors from the simplified
risk score model are female gender, smoking status, postoperative
opioid consumption, and a history of PONV/PDNV or motion
sickness (8). Each factor has a value of 1, which gives a range
of 0–4 when added together, 0 being low-risk and 4 signaling
high-risk patients (1, 8–10). The SAMBA Consensus Guidelines
for theManagement of PONV recommend assessing patient’s risk
factors and providing treatment to prevent PONV. In addition,
SAMBA recommends prophylactic combined therapy in subjects
with moderate and high risk for PONV (1, 11). Considering the
potentially catastrophic effects of vomiting on intracranial pres-
sure and postoperative hemorrhage for post-craniotomy patients,
a long-lasting antiemetic profile might be favorable for postoper-
ative patient care and may diminish post-surgical complications
(4, 12, 13). The Apfel scale predicts a PONV incidence of 60–80%
in subjects with moderate to severe risks (8). However, our study
reported a PONV incidence of 33%; these results support our
hypothesis that application of TDS within 2 h prior to surgery
and the IV administration of ondansetron and dexamethasone
immediately after anesthesia induction is an alternative regimen to
reduce the incidence of PONV in subjects undergoing craniotomy
under general anesthesia.
The literature describes adverse events associated with the use
of TDS as generally mild (1, 2, 21, 27). The most frequent adverse
event reported is dryness of mouth (29–91%); and other less com-
mon drug reaction are drowsiness (<16.6%), dizziness (8–12%),
blurred vision (<8%), and disorientation (<1%) (1, 2, 21, 27). The
results from our study did not show significant incidence of any of
the most common adverse events related with TDS; particularly
dry mouth, which is a symptom that could be difficult to assess
in neurosurgical settings and commonly reported preoperatively
settings as well (21). In addition, our results showed that the
administration of this prophylactic regimen did not significantly
increase the QTc interval in the ECGs.
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TABLE 4 | Apfel comparison in PONV 24h: literature versus our findings.
Apfel risk
factor
N PONV 24h PONV 24h
(Apfel) (%)
p-Value CI
2 13 (36.1%) 2 (15.4%) 40 0.071 [0.04, 0.42]
3 15 (41.7%) 4 (26.7%) 60 0.008 [0.11, 0.52]
4 8 (22.2%) 6 (75.0%) 80 0.723 [0.41, 0.92]
The incidence of PONV in patients with three Apfel’s risk
factors is 60% (recorded in the literature) (8) and our results
showed an incidence of only 26.7% (8) (Table 4). Gan et al.
confirmed the effectiveness of TDS with data collected from 0
to 48 h postoperative; they included one of the largest sample
size populations to date (10). The study assessed the effectiveness
of the use of TDS plus ondansetron compared with a placebo
patch plus ondansetron as a preventing treatment for PONV
in approximately 620 female patients that underwent outpatient
laparoscopic or breast augmentation procedures (10). This study
found a significant reduction in PONV 24 h after surgery in the
group who received a combination of TDS and ondansetron; 48%
of subjects that received a combination of TDS and ondansetron
and 39% that received only ondansetron did not experience vom-
iting and did not require rescue medication (10). Even TDS has
a slow onset of action, this study showed that clinical benefits
seemwhenTDS is applied 2 h before induction of anesthesia when
it is used in a combination with ondansetron (10). In addition,
this trial reported that the overall incidence of adverse events was
less frequent in the group receiving TDS in combination with
ondansetron compared with the group receiving ondansetron
alone (10).
Latz et al. presented a prospective study that evaluated the inci-
dence and risks factors of PONV in 229 subjects after craniotomies
(5). They found an incidence of PONV during the first 24 h after
surgery of 47% and identified absence of intraoperative steroids as
a risk factor (5). In our study, the use of dexamethasone as a potent
antiemetic on the triple therapy on subjects after craniotomy
reduced PONV considerably.
Lee HK et al. demonstrated that the combination of TDS
plus dexamethasone was more effective in complete remission of
PONV compared with dexamethasone alone or dexamethasone
plus ramosetron (82.5 versus 47.5, and 50.0%, respectively) in 120
subjects who underwent major orthopedic surgery with patient-
controlled analgesia via epidural route (15). A few limitations
of this study included the lack of a control-group without pro-
phylaxis, PONV assessments were performed only for 24 h after
surgery and all subjects had an indwelling urinary catheter; thus,
the side effect of TDS on urinary retention was not assessed
(15, 16).
Habib et al. designed a study comparing the combination of
aprepitant and dexamethasone versus ondansetron and dexam-
ethasone for PONV prophylaxis in subjects that underwent cran-
iotomy (4). They reported an accumulative incidence of PONV
during the first 24 h, 36% with ondansetron and 14% with aprepi-
tant. However, the difference of nausea and rescuemedication was
not statistically significant (4).
Lee et al. designed a similar randomized study that assessed
the efficacy of the administration of TDS and ondansetron IV to
prevent nausea after uterine artery embolization compared with
ondansetron IV alone (16). Overall, the incidence of nausea after
this procedure was low; there was a lower level of nausea with
those treated with TDS compared with placebo during the first
24 h after embolization (16). Adverse events were more com-
mon in the TDS group, with two subjects experiencing episodes
of profound disorientation and 71% reported considerable dry
mouth (16). Their results showed that TDS offers moderate
reduction of nausea; but, it was associated with occasional but
notable episodes of disorientation. Therefore, according to their
findings, the decision of using TDS should be based on care-
ful consideration of the potential benefits and undesirable side
effects (16). No adverse events associated with scopolamine were
found (16).
The literature reported an incidence of nausea after craniotomy
considerably variable, ranging from 43 to 70% (4–7) and vomiting
from 33% (28) to 55% (5). In another study designed by Fabling
et al., a randomized double blinded study compared ondansetron,
droperidol, and placebo after supratentorial craniotomy showed
that the incidence of PONV during the first 24 h was 35, 30, and
70%, respectively (6).
Our study had its limitations that should be considered. First,
it was a pilot study with the analysis of 36 subjects with no
control group. Its primary objective was the assessment of efficacy
and safety of triple therapy with TDS in craniotomies. Second,
ondansetron was administered during induction of anesthesia
as recommended in the package insert rather than used at the
end of surgery as suggested by the latest PONV guidelines (1).
Third, all subjects left the operation room with an indwelling
urinary catheter, and thus the effects of TDS on urinary reten-
tion could not be assessed. In addition, TDS was removed 24
h after the end of surgery; future studies should maintain the
TDS for 72 h and assess efficacy for PONV and PDNV. In
addition, we acknowledge another crucial limitation form this
pilot study, which is the difficulty to properly assess common
adverse events (dry mouth, drowsiness, dizziness, etc.) associated
with TDS application in the neurosurgical setting. Therefore, our
results need to be interpreted with caution and new prospective,
control-group and randomized trials are needed to address these
limitations.
Conclusion
The primary efficacy of the study was to determine the effi-
cacy and safety of using a prophylactic triple therapy with TDS,
ondansetron, and dexamethasone to prevent PONV. Our data
showed a PONV incidence of 33% and accumulative incidence of
nausea and vomiting of 38% 120 h after surgery. In addition, our
results showed that the triple therapy regimen used in this study
may be an efficient alternative regimen for PONV prophylaxis
in subjects undergoing neurological surgery with general anes-
thesia. Further studies using regimens affecting different receptor
pathways should be performed to better prove the efficacy in
preventing PONV.
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